Key Highlights
- ECO Animal Health rose 10.38% to 101p after results showed higher sales, margins and profit, alongside the launch of its first poultry vaccine.
- FY2026 revenue increased 10% to £87.5 million and adjusted EBITDA rose 16% to £8.5 million, with gross margin improving to about 49%.
- Year-end net cash was £25.4 million and £15 million of renewed bank facilities remained undrawn, supporting continued self-funded R&D.
ECO Animal Health Group plc (LSE: EAH) gained 10.38% to 101p on the latest UK market-movers screen. The move came after a strong set of annual results and the commercial launch of ECOVAXXIN MS, the company's first internally developed poultry vaccine. Those developments give investors a clearer growth narrative than a simple momentum trade: a profitable established antibiotic business is beginning to produce a second product platform.
There is still room for surprise in both directions. Vaccine approvals could diversify revenue and lift margins, but livestock cycles, China weakness, currency movements and development risk can alter outcomes. The key question is whether ECO can commercialise its pipeline while preserving the cash generation of Aivlosin.
Company Overview
ECO develops and markets veterinary products for livestock health. Its lead commercial product, Aivlosin, is an antibiotic used to treat respiratory and intestinal disease in pigs and poultry and is distributed in more than 70 markets. The group is also investing in vaccines and other preventative medicines, using the cash generated by the core business to fund development.
The strategy aims to reduce reliance on one antimicrobial franchise. Pipeline value still depends on approval, manufacturing, distribution and farmer adoption.
Why The Shares Are Attracting Attention
The July results exceeded upgraded expectations. Revenue, adjusted EBITDA, profit before tax and earnings per share all rose, while gross margin expanded. North America and Latin America grew strongly, and the company launched ECOVAXXIN MS in Europe after receiving marketing authorisation ahead of schedule. First orders have been received.
Aivlosin supplies cash and distribution, while vaccines add diversification. With no same-day update, post-results buying, launch enthusiasm and small-cap liquidity may all have influenced the rise.
Latest Financial Performance
For the year ended 31 March 2026, reported revenue increased 10% to £87.5 million from £79.6 million. Constant-currency revenue was £91.0 million, 14% higher. Gross margin improved to 48.6% from 45.1%, and adjusted EBITDA rose 16% to £8.5 million, producing a 9.8% margin. Profit before tax increased 35% to £5.4 million, while earnings per share rose 31% to 3.26p.
Research and development expenditure increased to £8.8 million as planned. The board did not recommend a dividend because it continues to reinvest in the pipeline. That policy can create value if approvals lead to profitable sales, but it also means shareholders depend on capital appreciation rather than current income.
Operational Performance
North American revenue grew 22% to £26.1 million, and Latin America advanced 15% to £18.8 million. China and Japan increased 5% for the year, although Chinese trading slowed late in the period as poor pork economics reduced treatment demand. Excluding India, South and Southeast Asia recovered strongly; India remained difficult because of market conditions and distributor credit risk.
Pricing, lower input costs and geographic mix lifted margins. ECO's existing commercial network can carry vaccines into new markets, but currency and generic competition remain.
Balance Sheet, Cash Flow And Funding
Net cash was £25.4 million at year-end, slightly above £25.0 million a year earlier, and operating cash flow was approximately £7.7 million. The company renewed a £10 million revolving credit facility and a £5 million overdraft for five years on improved terms; both were undrawn at the results date.
The balance sheet allows ECO to fund R&D internally, which limits near-term dilution risk. However, 39% of cash was held outside China, meaning a majority remained within that market and may be subject to currency, regulatory or repatriation considerations. Pipeline spending and business-development deals can also raise future cash requirements.
Recent Announcements And Strategic Developments
ECOVAXXIN MS launched in Europe in July 2026 and received initial orders. The company is pursuing approvals beyond the EU, including the United States, Thailand and Argentina. Its second Mycoplasma poultry vaccine, ECOVAXXIN MG, received a favourable USDA safety assessment, while other programmes are moving through development.
A new business-development lead will seek in-licensing opportunities. Any deal must fit the commercial platform and earn adequate returns, while ERP work targets efficiency.
Industry And Economic Backdrop
Livestock producers demand treatments that protect animal welfare, productivity and food supply. Disease outbreaks can increase product use, while weak farm economics can delay treatment or reduce stocking. Pork and poultry cycles therefore affect sales even when a medicine has strong clinical value.
Antimicrobial stewardship supports prevention and vaccines, but approval standards are rigorous. Currency, tariffs and local distribution add complexity to global sales.
Potential Growth Drivers
The immediate growth opportunity is the European roll-out of ECOVAXXIN MS through ECO's existing network. US approval would expand the addressable market, while registrations in additional countries could extend the product's lifecycle. European launch data can support pricing, distributor education and later submissions in additional territories. Aivlosin can continue to grow through disease-control programmes, new customers and geographic recovery.
Management expects up to nine products to receive US or EU approval over the next five to six years. Not every candidate will succeed, but a portfolio approach reduces dependence on any one development programme. In-licensing could accelerate growth if the group finds products that use its commercial infrastructure efficiently.
Upcoming Milestones Or Catalysts
Investors should monitor early vaccine orders, gross margin and the timing of US regulatory decisions. Management expects US approval for ECOVAXXIN MS by the end of calendar 2026, although regulatory outcomes remain uncertain. Further label data, submissions in new territories and progress on ECOVAXXIN MG are also relevant.
The next trading update will show whether weakness in China is being offset by North America, Latin America and Southeast Asia. Cash generation after higher R&D spending will indicate how comfortably the pipeline remains self-funded.
Principal Risks And Uncertainties
Aivlosin still represents a large share of sales, creating product concentration and generic-competition risk. Livestock prices, disease prevalence and distributor finances can change demand. Vaccine candidates may fail trials, face regulatory delays or launch more slowly than expected. Manufacturing or quality problems could interrupt supply.
Currency movements can reduce reported revenue and profit. Cash held in different jurisdictions may not be fully interchangeable. The absence of a dividend means returns depend on execution and valuation. Small-cap liquidity can amplify price movements after news.
Investment Perspective
ECO's FY2026 performance was strong: sales, margin, profit and cash all moved in the right direction. The first vaccine launch is strategically important because it turns years of R&D spending into a commercial test and begins diversifying the portfolio. Early repeat orders will be the clearest measure of distributor and farmer acceptance across core European markets.
The market should still demand evidence of adoption. Early orders are encouraging, but sustainable vaccine revenue, additional approvals and resilience in China will determine whether the company can deliver a higher-growth profile. The balance sheet gives management time, not certainty.
Outlook
ECO Animal Health (LSE: EAH) could surprise the market if its vaccine platform scales faster than expected while Aivlosin remains healthy. The 10.38% rise is supported by improved FY2026 results, strong net cash and the ECOVAXXIN MS launch. Investors should balance that progress against livestock cyclicality, product concentration and the unavoidable risks of veterinary drug development.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...